From 13 till 17 September 2024: HIGHLIGHTS FROM ESMO
Your direct line with Barcelona
The European Society of Medical Oncology (ESMO) 2024 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Barcelona, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
Daily highlights in skin cancer
Prof Bart Neyns, medical oncologist at UZ Brussel shares the key insights from the proffered paper session.
An updated pooled analysis from INMC with a three-year follow-up of patients treated
While ESMO did not feature any practice-changing presentations in the field of melanoma, it did provide interesting, long-term updates of pivotal clinical trials in addition to important insights from real-world
In-depth stories about skin cancer
In this video Prof Dr Bart Neyns and Prof Dr John Haanen, medical oncologists, respectively at the University Hospital Brussels and at the National Cancer Institute in Amsterdam, share their
In this video, Prof Dr Jeroen Mebis (Jessa Hospital, Hasselt, Belgium) shares the long-term results of this trial presented at ESMO 2024.
In this video, Prof Dr Bart Neyns, medical oncologist at the University Hospital Brussels, provides a brief overview of the recent changes in the treatment landscape for melanoma patients and
In this video Prof Dr Jeroen Mebis, medical oncologist at the Jessa Hospital in Hasselt, shares the key take-aways from the updated analysis of the KEYNOTE-716 trial presented at ESMO
Prof Jeroen Mebis, medical oncologist at Jessa Hospital in Hasselt, Belgium, shares his key insights on the KEYNOTE-006 study.
Prof Dr Anne Rogiers is a psychiatrist working in the CHU Brugmann in Brussels. During ESMO 2024, Prof Rogiers discussed the issue of cognitive impairment in cancer survivors and explained
Skin cancer poster selection
From a poster presented by Ms Nathalie Vanlaer, psychologist at the University hospital Brussels, it became clear that 55% of long-term advanced melanoma survivors continues to have fears for recurrence.
During ESMO 2024, Dr Manon Vounckx (University hospital Brussels) presented the results obtained with a treatment of IV nivolumab (10 mg q2w), IT ipilimumab (10 mg qw), IT AS01b (50
During ESMO 2024, Dr Iris Dirven, medical oncologist in training at the University Hospital Brussels, shared the results obtained with regorafenib in 8 KIT-mutant advanced melanoma patients who exhausted all
During ESMO 2024, Dr Meredith McKean (Sarah Cannon Research Institute, Memphis, TN, USA) presented updated results of this trial with 12 months of additional follow-up.
In this video, Prof Dr Jeroen Mebis (Jessa Hospital, Hasselt) discusses the 7-year update of this trial which was presented as a poster during the 2024 annual ESMO meeting.
Made possible with the financial support of our partners.
All videos are developed independently and are non-promotional.
